Aktis Oncology, Inc. — fact timeline

Aktis Oncology, Inc. reported the year ended December 31, 2025 results: revenue $6.5 million.

“the January 2026 IPO. The Company believes that the pro forma as adjusted cash position will fund its operations into 2029. • Collaboration revenue: Collaboration revenue was $6.5 million for the year ended December 31, 2025, compared to $1.5 million for the year ended December 31, 2024. The increase was attributable to revenue recognized under the Company’s”

Aktis Oncology, Inc.: Amended and restated bylaws to establish procedures for stockholder proposals and director nominations, modify indemnification provisions, and conform to amended charter (effective 2026-01-12).

“the amended and restated bylaws of the Company (the “Amended and Restated Bylaws”), became effective as of immediately prior to the completion of the IPO on January 12, 2026. The Amended and Restated Bylaws amend and restate the Company’s bylaws in their entirety to, among other things: (i) establish procedures relating to the presentation of stockholder proposals at stockholder meetings; (ii) establish procedures relating to the nomination of directors; (iii) modify the indemnification provisions for the Company’s directors and officers, and (iv) conform to the amended provisions of the Amended and Restated Certificate.”

Aktis Oncology, Inc.: Amended and restated certificate of incorporation to authorize additional common/preferred stock, eliminate existing preferred series, change director removal vote threshold, establish classified board, and eliminate stockholder action by written consent (effective 2026-01-12).

“on January 12, 2026, the Company filed its amended and restated certificate of incorporation (the “Amended and Restated Certificate”) with the Secretary of State of the State of Delaware. The Amended and Restated Certificate amends and restates the Company’s existing sixth amended and restated certificate of incorporation, as amended, in its entirety to, among other things: (i) authorize 480,000,000 shares of Common Stock and 10,000,000 shares of Class A common stock, par value $0.0001 per share; (ii) eliminate all references to the previously-existing series of preferred stock; (iii) authorize 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Company’s board of directors (the “Board”) in one or more series; (iv) require the approval of at least two-thirds of the shares entitled to vote to remove a director for cause; (v) establish a classified Board, as a result of which, the successors to the directors whose terms have expired will be elect”